An Open-Label Single-Arm Phase I/IIa Study to Evaluate the Safety of Human Allogeneic Bone-Marrow-Derived Mesenchymal Stromal Cell Product StromaForte ® for the Treatment of Knee Osteoarthritis
This open-label Phase I/IIa study demonstrated that a single intra-articular injection of the allogeneic bone-marrow-derived mesenchymal stromal cell product StromaForte® is safe and well-tolerated in patients with grade 2–3 knee osteoarthritis, resulting in improved pain and function alongside significant systemic immunological remodeling.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Knee osteoarthritis is a slow, grinding wear and tear that affects millions of people, turning the smooth cushion between bones into rough, painful surfaces. It is a condition driven not just by physical damage, but also by a low-level, persistent inflammation that keeps the joint angry and stiff. For decades, doctors have treated the pain with pills or temporary lubricants, but these options rarely stop the disease from getting worse. In recent years, scientists have turned their attention to a different kind of therapy: using living cells to calm the joint and perhaps help it heal. These cells, known as mesenchymal stromal cells, are found in bone marrow and are famous for their ability to soothe the immune system and reduce inflammation. While some studies have looked at cells taken from a patient's own body or from fat tissue, researchers have been curious about whether cells from a healthy donor, grown in a lab and injected into the knee, could offer a safer and more consistent way to treat this painful condition.
A team of researchers recently tested this idea in a small, early-stage clinical trial involving twelve adults with mild to moderate knee osteoarthritis. The study focused on a specific product called StromaForte, which consists of millions of bone-marrow cells harvested from young, healthy donors in Sweden. These cells were grown in a laboratory until there were enough to make a single dose, then frozen and shipped to a hospital in Abu Dhabi. On the day of the procedure, the frozen cells were thawed and carefully washed to remove the preservatives. An orthopedic surgeon then used ultrasound to guide a needle directly into the knee joint of each participant, injecting a precise amount of 50 million cells. The goal was simple: to see if this single injection was safe and to watch how the patients felt over the next six months.
The results were encouraging regarding safety. For the first two hours after the injection, none of the participants showed any signs of an immediate reaction, such as a fever or a spike in blood pressure. Over the following six months, most people reported some minor discomfort, such as swelling or pain at the injection site, but these issues were mild and cleared up on their own within a few days. No one suffered a serious medical event linked to the treatment, and blood tests showed no dangerous changes in the patients' overall health. The study confirmed that putting these donor cells into the knee did not trigger a harmful immune response or cause new damage to the joint structure.
Beyond safety, the researchers looked closely at how the treatment affected the patients' daily lives. They asked participants to rate their pain and track how well they could walk, climb stairs, and perform daily tasks. The numbers told a clear story of improvement. Before the injection, the average pain score was high, but by the third month, it had dropped significantly, and by the sixth month, it had fallen even further. Patients also reported feeling more capable in their daily activities and experiencing a better quality of life. While the study was not designed to prove that the cells could reverse the physical damage seen on X-rays, the scans taken at the end of the six months showed that the disease had not gotten worse. In fact, for a few individuals, the images suggested a slight improvement in the cartilage, though the researchers noted that a longer period of observation would be needed to confirm such structural changes.
Perhaps the most surprising discovery came from analyzing the patients' blood. Even though the cells were injected only into the knee, the treatment seemed to send a ripple effect through the entire body's immune system. Six months after the injection, the blood contained higher levels of specific immune cells known as memory T-cells and regulatory B-cells, which are associated with a calmer, more balanced immune response. At the same time, the levels of certain inflammatory cells dropped. This suggests that the cells did not just work locally to soothe the knee, but may have helped retrain the body's broader defense system to be less aggressive. The study did not find changes in the levels of inflammatory chemicals circulating in the blood, which hints that the immune system's response might be more complex than a simple rise or fall in specific proteins.
This trial provides a solid foundation for future research. It showed that a single injection of these donor cells is safe for people with knee osteoarthritis and is linked to meaningful relief from pain and improved function. The changes observed in the immune system offer a new clue about how these cells might work, suggesting they could help reset the body's inflammatory balance from the inside out. While the study was too small to declare a cure, and the six-month timeline is too short to know if the benefits will last a lifetime, the findings are a strong signal that this approach deserves further investigation. Larger studies with more patients and longer follow-up periods will be needed to confirm whether this treatment can truly alter the course of knee osteoarthritis and provide lasting relief for those living with the disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.